NEW YORK (GenomeWeb News) – Trilink BioTechnologies said today that it has inked a new licensing agreement with Biofortuna allowing the UK firm to use Trilink's hot start deoxynucleotides for freeze-drying molecular diagnostic kit development and production service.

Biofortuna offers this product to "diagnostic companies looking to develop stabilized molecular diagnostic kits," said Mike Bunce, chief science officer of Biofortuna, in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.

The US Supreme Court has declined to review a decision involving the use of "inadvertently shed" DNA in a police investigation and subsequent conviction.

A panel at the New York Times discusses anonymity and privacy of users of 23andMe's services when access to its database is offered for research.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.